Privium intends to sell 10% of its special purpose vehicle for $50 million to monetize its rights related to a generic insulin transaction. Privium I holds 25% of Elona Biotechnology's common equity and has rights to manufacture, market, and sell insulin and related products in specified territories. The proceeds will be used to finalize the acquisition of rights from Elona and for regulatory and corporate purposes.
documents/EFTA00753655.pdf
{}